Voyager Therapeutics is trading 5.23% up in pre-market at $2.39 on October 13, with no clearly confirmed company-specific announcement explaining the move.
- The shares closed at $2.27 on October 12.
- A pipeline and strategy update on the company’s 2026 CNS programs was reported October 9; it is not a fresh October 13 catalyst.
- Broad market signals are mixed and do not clearly explain the stock-specific gain; the available context does not establish a reason.